Memantine hydrochloride

  title={Memantine hydrochloride},
  author={A. Witt and Nancy Macdonald and P. Kirkpatrick},
  journal={Nature Reviews Drug Discovery},
Memantine hydrochloride (Namenda; Forest/Merz), which acts to protect neurons against toxicity caused by overactivation of N-methyl-D-aspartate receptors, became the first drug to be approved by the US FDA for the treatment of moderate to severe Alzheimer's disease in October 2003, after its approval for the same indication in the European Union in 2002. What influence could this have on its market potential? 
Pharmacokinetics of Memantine-derivative MN-08 in Rats: A Preclinical Study
1-amino-3-methyl-5-nitrate methyl adamantane hydrochloride (MN-08), a novel nitrate derivative of memantine, was found to be a potent candidate compound for the treatment of Alzheimer disease in anExpand
Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease.
A new hypothesis has been proposed that a combination of galantamine, memantine and lycopene is anticipated to produce better activity as compared to the current therapies available in market for the treatment of this disease. Expand
Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Kynurenic acid (KYNA) is an endogenous antagonist of NMDA receptors which has been demonstrated under experimental conditions to be neuroprotective and may offer a novel therapeutic option for the treatment of neurodegenerative disease and pain syndromes. Expand
Memantine in neurological disorders - schizophrenia and depression.
Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist and there is a belief that memantine may also benefit other conditions such as schizophrenia and depression. Expand
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
This study investigated the anti-dyskinetic properties of memantine, a non-competitive NMDA receptor antagonist in clinical use for the treatment of dementia, in the 6-hydroxy-dopamine (6-OHDA)-lesion rat model of Parkinson's disease and showed that memantine significantly dampened dyskinesia in both drug-naïve and L-DOPA-primed rats, but only during the first few days of administration. Expand
Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine
It is suggested that a single dose of memantine produces an early anxiogenic response in the emotion-potentiated startle similar to that seen following a single doses of the selective serotonin reuptake inhibitor, citalopram, however the overall profile of effects is more limited than that which might be expected in response to a conventional antidepressant. Expand
A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory
Overall, the opportunity to induce a selective cognitive deficit in attention (5CSRT) or working memory (DMTP) in the rat is limited by both the NMDAR antagonist and the dose range used. Expand
Mechanism of block and behavioral effects of the N-methyl-D-aspartate receptor antagonists memantine and ketamine
Pharmacological inhibition of NMDA receptor activity by ketamine is accompanied by pyschotomimetic side-effects; however, the Alzheimer's disease therapeutic memantine blocks NMDA receptor activityExpand
Therapeutic efficacy of novel memantine nitrate MN‐08 in animal models of Alzheimer’s disease
MN‐08, a novel memantine nitrate, was found to inhibit Aβ accumulation, prevent neuronal and dendritic spine loss, and consequently attenuate cognitive deficits in 2‐month‐old APP/PS1 transgenic mice and in the 8‐ month‐old triple‐transgenic (3×Tg‐AD) mice (for a 4‐month therapeutic course). Expand
Mechanisms of NMDA receptor inhibition by memantine and ketamine
NMDA receptors (NMDARs), a subfamily of ionotropic glutamate receptors, have unique biophysical properties including high permeability to Ca2+. Activation of NMDARs increases the concentration ofExpand


Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data
Preclinical data on memantine is summarized to provide evidence that it is indeed possible to develop clinically well tolerated NMDA receptor antagonists, a fact reflected in the recent interest of several pharmaceutical companies in developing compounds with similar properties to memantine. Expand
NMDA receptor pathways as drug targets
The future prospects for drugs that act on NMDA receptor pathways are critically assessed, including potential treatments for some major disorders such as stroke and Alzheimer's disease, for which effective therapies are still lacking. Expand
Memantine in Moderate-to-severe Alzheimer's Disease
Alzheimer’s disease (AD) is the most common cause of dementia. It is a progressive neurodegenerative disorder resulting in cognitive and behavioural impairment of sufficient severity to markedlyExpand
Treatment of Alzheimer's disease.
Alzheimer's disease, which is characterized by progressive loss of memory and cognitive function, affects 15 million people worldwide. The incidence increases steadily from 0.5 percent per year atExpand
Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels.
  • J. Bormann
  • Chemistry, Medicine
  • European journal of pharmacology
  • 1989
The adamantyl group in medicinal agents. II. Anabolic steroid 17-beta-adamantoates.